Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- 94% OF PATIENTS (51 OF 54) REMAINED FREE FROM THE BURDEN OF CONTINUOUS PROPHYLAXIS TREATMENT THROUGH FIVE YEARS FOLLOWING A SINGLE INFUSION OF HEMGENIX, DEMONSTRATING SUSTAINED THERAPEUTIC BENEFIT- AT YEAR FIVE, MEAN FACTOR IX ACTIVITY LEVELS REMAINED STRONG AT 36.1% ANDHEMGENIX CONTINUED TO DEMONSTRATE A FAVORABLE SAFETY PROFILE, REINFORCING ITS DURABLE EFFICACY- MORE THAN 75 INDIVIDUALS ACROSS EIGHT COUNTRIES HAVE RECEIVEDHEMGENIX IN REAL-WORLD SETTINGS, REFLECTING GROWING GLOBAL ADOPTION KING OF PRUSSIA, PA. , DEC. 7, 2025 /PRNEWSWIRE/ --GLOBAL BIOPHARMA LEADER CSL (ASX:CSL; USOTC:CSLLY) TODAY ANNOUNCED FIVE-YEAR (60-MONTH) RESULTS FROM THE PIVOTAL PHASE 3 HOPE-B STUDY, CONFIRMING THE LONG-TERM DURABILITY AND SAFETY OF A ONE-TIME INFUSION OF HEMGENIX (ETRANACOGENE DEZAPARVOVEC-DRLB) IN ADULTS LIVING WITH HEMOPHILIA B.

DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE CONFIRM THE LONG-TERM DURABILITY AND SAFETY OF HEMGENIX (ETRANACOGENE DEZAPARVOVEC-DRLB) OVER FIVE YEARS

LEXINGTON, MASS. AND AMSTERDAM, DEC. 04, 2025 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THAT THE COMPANY RECEIVED FINAL MEETING MINUTES FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) REGARDING A PRE-BIOLOGICS LICENSE APPLICATION (BLA) MEETING HELD ON OCTOBER 29, 2025 TO DISCUSS THE APPLICATION FOR AMT-130, AN INVESTIGATIONAL GENE THERAPY FOR HUNTINGTON'S DISEASE (HD).

UNIQURE PROVIDES REGULATORY UPDATE ON AMT-130 FOR HUNTINGTON'S DISEASE

NEW YORK , NOV. 20, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF UNIQURE N.V. ("UNIQURE" OR THE "COMPANY") (NASDAQ: QURE).

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF UNIQURE N.V. - QURE

LOS ANGELES , NOV. 14, 2025 /PRNEWSWIRE/ --THE DJS LAW GROUPANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF UNIQURE N.V. ("UNIQURE" OR "THE COMPANY") (NASDAQ: QURE) FOR VIOLATIONS OF THE SECURITIES LAWS.

UNIQURE N.V. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - QURE

LOS ANGELES , NOV. 11, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUPANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF UNIQURE N.V. ("UNIQURE" OR "THE COMPANY") (NASDAQ: QURE) FOR VIOLATIONS OF THE SECURITIES LAWS.

~ ANNOUNCED PIVOTAL TOPLINE DATA FROM PHASE I/II STUDY OF AMT-130 IN HUNTINGTON'S DISEASE MET ITS PRIMARY AND KEY SECONDARY ENDPOINTS, DEMONSTRATING STATISTICALLY SIGNIFICANT SLOWING OF DISEASE PROGRESSION AT 36 MONTHS AND SUPPORTIVE TRENDS ACROSS KEY CLINICAL AND BIOMARKER ENDPOINTS ~

UNIQURE ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

~ UNIQURE TO HOST EARNINGS CALL ON MONDAY, NOVEMBER 10, 2025 AT 8:30 A.M. ET ~ ~ UNIQURE TO HOST EARNINGS CALL ON MONDAY, NOVEMBER 10, 2025 AT 8:30 A.M. ET ~

UNIQURE TO ANNOUNCE THIRD QUARTER 2025 FINANCIAL RESULTS

LOS ANGELES--(BUSINESS WIRE)--UNIQURE N.V. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  QURE.

UNIQURE N.V. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  QURE

LEXINGTON, MASS. AND AMSTERDAM, NOV. 03, 2025 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THAT IT RECEIVED FEEDBACK FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) DURING A RECENT PRE-BIOLOGICS LICENSE APPLICATION (BLA) MEETING REGARDING AMT-130, AN INVESTIGATIONAL GENE THERAPY FOR HUNTINGTON'S DISEASE (HD).

LEXINGTON, MASS. AND AMSTERDAM, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 6,736,841 ORDINARY SHARES AT A PUBLIC OFFERING PRICE OF $47.50 PER SHARE, WHICH INCLUDES 947,368 ORDINARY SHARES ISSUED PURSUANT TO THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL ORDINARY SHARES IN THE OFFERING; AND, IN LIEU OF ORDINARY SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 526,316 OF ITS ORDINARY SHARES AT THE PUBLIC OFFERING PRICE PER SHARE LESS THE $0.0001 PER SHARE EXERCISE PRICE OF EACH PRE-FUNDED WARRANT. THE AGGREGATE GROSS PROCEEDS TO UNIQURE FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY UNIQURE, WERE APPROXIMATELY $345 MILLION. ALL SECURITIES IN THE OFFERING WERE SOLD BY UNIQURE.

uniQure N.V.

QURE

Price

Financial Reports

No items found.

Press Releases

uniQure N.V.

QURE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

QURE